Company intelligence / Profile preview

Modi-Mundipharma

New Delhi, Delhi, India

Ownership: Private
Development stage: Other

Overview

Modi-Mundipharma is an active, privately-owned pharmaceutical company in India focusing on pain management, respiratory, cardiovascular, diabetes, and hospital nutrition products. It commercializes branded drugs and nutritionals, including long-acting pain and asthma therapies, some utilizing proprietary Continus Technology. Selected nutrition products have completed clinical studies for enteral feeding in hospital settings.

Therapeutic areas: EndocrinologyRheumatologyMetabolic DisordersPulmonologyCardiovascularNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Mundipharma Group (Switzerland)Zambon (Italy)Sigma-Tau (Italy)Norgine (Netherlands)Anika Therapeutics (USA)Lavipharm (Greece)

Beyond the preview

Go deeper on Modi-Mundipharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modi-Mundipharma.

Explore the full profile